<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02073305</url>
  </required_header>
  <id_info>
    <org_study_id>CIRS-SASinHD_003</org_study_id>
    <nct_id>NCT02073305</nct_id>
  </id_info>
  <brief_title>Prognostic Impact of Sleep Apnea on Cardiovascular Morbidity and Mortality, in End Stage Renal Disease Patients</brief_title>
  <acronym>SASinHD_003</acronym>
  <official_title>Prognostic Impact of Sleep Apnea on Cardiovascular Morbidity and Mortality, in End Stage Renal Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prospectively evaluate the impact of sleep apnea on the
      cardiovascular morbidity and mortality of patients with end-stage renal disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sleep apnea is more prevalent in end stage renal disease patients than in the general
      population, and may participate to the increased cardiovascular mortality observed in this
      group of patients. Despite a significant increase in knowledge about the harmful effects of
      obstructive sleep apnea in the general population, the prognostic impact of sleep apnea in
      the end stage renal disease population has not yet been investigated.

      The purpose of this trial is to investigate the hypothesis that moderate to severe sleep
      apnea increase the risk of major cardiovascular events in patients with end stage renal
      disease.

      The severity of sleep apnea is measured at inclusion and the patients are followed during 3
      years to assess the cardiovascular end-points. The result of the sleep study is communicated
      to the treating physician and the decision whether to treat or not sleep apnea is left to the
      treating physician, independently of the study protocol. The comparison will include three
      groups: patients without sleep apnea, untreated patients with moderate to severe sleep apnea
      and treated patients with sleep apnea.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Time to first major cardiovascular event</measure>
    <time_frame>3 years</time_frame>
    <description>composite end-point of all-cause mortality, acute myocardial infarction, hospitalization for acute myocardial ischemia, acute heart failure, stroke, acute peripheral vascular event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to cardiovascular death</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first non-fatal acute myocardial infarction</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first hospitalization for acute myocardial ischemia</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first acute heart failure</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first non-fatal stroke</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first acute peripheral vascular event</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>No sleep apnea</arm_group_label>
    <description>Subjects with no or light sleep apnea (AHI &lt; 15/h)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleep Apnea - untreated</arm_group_label>
    <description>Subjects with moderate to severe sleep apnea (AHI ≥15/h) and no specific treatment.
Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleep Apnea - treated</arm_group_label>
    <description>Subjects with treated moderate to severe sleep apnea (AHI ≥15/h). Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Sleep Apnea</intervention_name>
    <description>No intervention</description>
    <arm_group_label>No sleep apnea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sleep Apnea - untreated</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Sleep Apnea - untreated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sleep Apnea - treated</intervention_name>
    <description>Sleep Apnea treatment by positive pression ventilation (CPAP/BIPAP) or sleep apnea oral appliance</description>
    <arm_group_label>Sleep Apnea - treated</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with end stage renal disease on renal replacement therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  end stage renal disease on renal replacement therapy

          -  age ≥ 18 years

        Exclusion Criteria:

          -  unstable congestive heart failure

          -  active psychiatric disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphaël Heinzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Investigation et Recherche sur le Sommeil (CIRS) - Centre Hospitalier Universitaire Vaudois (CHUV)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Ogna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Investigation et Recherche sur le Sommeil (CIRS) - Centre Hospitalier Universitaire Vaudois (CHUV)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valentina Forni Ogna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Investigation et Recherche sur le Sommeil (CIRS) - Centre Hospitalier Universitaire Vaudois (CHUV)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Investigation et Recherche sur le Sommeil (CIRS) - Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphaël Heinzer, MD</last_name>
      <phone>+41 21 314 67 48</phone>
      <email>raphael.heinzer@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Adam Ogna, MD</last_name>
      <phone>+41 21 314 67 48</phone>
      <email>adam.ogna@chuv.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Ogna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina Forni Ogna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphaël Heinzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Adam Ogna</investigator_full_name>
    <investigator_title>Centre d'Investigation et Recherche sur le Sommeil (CIRS)</investigator_title>
  </responsible_party>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>end stage renal disease</keyword>
  <keyword>cardiovascular events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

